Unicycive Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell UNCY and other ETFs, options, and stocks.

About UNCY

Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. 

CEO
Shalabh Gupta
CEOShalabh Gupta
Employees
22
Employees22
Headquarters
Los Altos, California
HeadquartersLos Altos, California
Founded
2016
Founded2016
Employees
22
Employees22

UNCY Key Statistics

Market cap
74.00M
Market cap74.00M
Price-Earnings ratio
-1.24
Price-Earnings ratio-1.24
Dividend yield
Dividend yield
Average volume
662.78K
Average volume662.78K
High today
$4.35
High today$4.35
Low today
$4.16
Low today$4.16
Open price
$4.25
Open price$4.25
Volume
410.27K
Volume410.27K
52 Week high
$11.00
52 Week high$11.00
52 Week low
$2.83
52 Week low$2.83

UNCY News

TipRanks 5d
Unicycive Faces Securities Lawsuit Over Drug Claims

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...

TipRanks 6d
Unicycive Therapeutics granted new U.S. patent for UNI-494 to treat CKD

Unicycive Therapeutics (UNCY) announced the issuance of U.S. Patent 12,377,082 by the U.S. Patent and Trademark Office for UNI-494 to treat Chronic Kidney Disea...

Analyst ratings

100%

of 7 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own UNCY. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.